
In a recent interview, Michael Hofman, MBBS, FRACP, discussed preliminary research findings and the potential utility of the positron emission tomography (PET) agent ITM-94, which recently garnered a fast track designation from the FDA for clear cell renal cell carcinoma (ccRCC).





























